DOI: https://doi.org/10.14710/dmj.v14i5.47148

CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA LEADING TO LIFE-THREATENING HYPOVOLEMIC SHOCK IN CERVICAL CANCER: A CASE REPORT

*Nurul Fadila  -  Department of Internal Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia, Indonesia
Raveinal Raveinal  -  Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia, Indonesia
Fadrian Fadrian  -  Division of Tropical and Infectious Disease, Department of Internal Medicine, Dr. M. Djamil Central General Hospital, Padang, Indonesia, Indonesia
Roza Mulyana  -  Division of Geriatric, Department of Internal Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia, Indonesia
Open Access Copyright 2025 Nurul Fadila, Raveinal Raveinal, Fadrian Fadrian, Roza Mulyana
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Citation Format:
Abstract
Hypovolemic shock due to acute hemorrhage is a life-threatening condition, particularly in cancer patients undergoing chemotherapy. Although recent studies have established protocols for managing hypovolemic shock in trauma and sepsis, the role of chemotherapy-induced thrombocytopenia in exacerbating post-procedural bleeding risks remains underexplored. This case emphasizes the clinical complexity of managing hemorrhagic shock in advanced-stage cervical cancer patients following percutaneous nephrostomy (PCN). Case Presentation: A 52-year-old female with stage IVB cervical cancer and liver metastasis presented with hypovolemic shock following PCN. She exhibited severe hematuria and chemotherapy-induced thrombocytopenia, leading to prolonged bleeding and subsequent shock. Initial management involved aggressive fluid resuscitation, blood transfusions, and correction of thrombocytopenia. Despite the challenges of managing shock in a patient with concurrent chronic kidney disease (CKD) stage IV, prompt intervention led to significant clinical improvement, stabilization of vital signs, and eventual discharge. Conclusion: This case highlights the importance of early intervention in managing hypovolemic shock in oncology patients with multiple comorbidities, including chemotherapy-induced thrombocytopenia and CKD. A multidisciplinary approach and close monitoring are crucial for improving outcomes in such high-risk patients. Further research is needed to establish tailored management protocols for this patient population.

Note: This article has supplementary file(s).

Fulltext View|Download |  common.other
Turnitin report
Subject
Type Other
  Download (1MB)    Indexing metadata
Keywords: Chemotherapy; Cervical cancer; Hypovolemic shock; Percutaneous nephrostomy; Thrombocytopenia

Article Metrics:

Article Info
Section: Case Report
Language : EN
Recent articles
THE RELATIONSHIP BETWEEN CLINICAL STAGE AND THERAPEUTIC RESPONSE AFTER COMPLETE RADIOCHEMOTHERAPY IN NASOPHARYNGEAL CARCINOMA WHO TYPE III IN NGOERAH HOSPITAL DENPASAR DIFFERENTIATING APPENDICITIS TYPES: THE ROLE OF NEUTROPHIL SUBTYPES HEPATIC NF-kB AND CYR61 SUPPRESSION BY HOLOTHURIA SCABRA METHANOL EXTRACT IN A HIGH-FAT DIET AND DMBA-INDUCED BREAST CANCER MOUSE MODEL PROGRESSION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO PROLYMPHOCYTIC LEUKEMIA: A RARE CASE REPORT CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA LEADING TO LIFE-THREATENING HYPOVOLEMIC SHOCK IN CERVICAL CANCER: A CASE REPORT More recent articles
  1. Sakthi Balan G, Aravind Raj S. A review on Shock tubes with multitudinous applications. Int J Impact Eng 2023;172. https://doi.org/10.1016/j.ijimpeng.2022.104406
  2. Bjorklund A, Resch J, Slusher T. Pediatric Shock Review. Pediatr Rev 2023;44. https://doi.org/10.1542/pir.2022-005630
  3. Shagana JA, Dhanraj M, Jain AR, Nirosa T. Hypovolemic shock - A review. Drug Invention Today 2018;10
  4. Jones TJ, Bhattacharya B, Davis KA. Hypovolemic Shock. Textbook of Emergency General Surgery: Traumatic and Non-traumatic Surgical Emergencies, 2023. https://doi.org/10.1007/978-3-031-22599-4_11
  5. Saito Y, Uchiyama K, Sakamoto T, Kubota K, Oki H, Iwai M, et al. Evaluation of chemotherapy regimen management practice by oncology-specialized and non-specialized pharmacists collaboration. Biol Pharm Bull 2021;44. https://doi.org/10.1248/bpb.b20-00872
  6. Gao A, Zhang L, Zhong D. Chemotherapy-induced thrombocytopenia: literature review. Discover Oncology 2023;14. https://doi.org/10.1007/s12672-023-00616-3
  7. Weycker D, Hatfield M, Grossman A, Hanau A, Lonshteyn A, Sharma A, et al. Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice. BMC Cancer 2019;19. https://doi.org/10.1186/s12885-019-5354-5
  8. Gurumurthy G, Kisiel F, Gurumurthy S, Gurumurthy J. Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: A meta-analysis. Journal of Oncology Pharmacy Practice 2023. https://doi.org/10.1177/10781552231219003
  9. Tamamyan G, Danielyan S, Lambert MP. Chemotherapy-induced thrombocytopenia in pediatric oncology. Crit Rev Oncol Hematol 2016;99. https://doi.org/10.1016/j.critrevonc.2016.01.005
  10. Baskett PJ. ABC of major trauma. Management of hypovolaemic shock. BMJ 1990;300. https://doi.org/10.1136/bmj.300.6737.1453
  11. Montañez RAC, Veloza CMC, Ballesteros LVM, González TVP, Leyva AJS. Postpartum hemorrhage: Nursing interventions and management to prevent hypovolemic shock. Revista Cuidarte 2022;13. https://doi.org/10.15649/cuidarte.2075
  12. Jali AGP, Nkambule BB. Prevalence and etiology of moderate and severe thrombocytopenia in a tertiary and quaternary centre in KwaZulu-Natal. Afr J Lab Med 2020;9. https://doi.org/10.4102/ajlm.v9i1.799
  13. Zhou S, Song B, Li C, Tang W, Zhang X, Jin X, et al. The predictive model for risk of chemotherapy-induced thrombocytopenia based on antineoplastic drugs for solid tumors in eastern China. Sci Rep 2023;13. https://doi.org/10.1038/s41598-023-27824-9

Last update:

No citation recorded.

Last update:

No citation recorded.